Longeveron Inc.
Business
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines, primarily allogeneic mesenchymal stem cell therapies, to address unmet medical needs. Its lead investigational product candidate, laromestrocel (Lomecel-B®), is in clinical development for hypoplastic left heart syndrome, Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty. The company operates a cGMP-compliant manufacturing facility in Miami, Florida that produces investigational product candidates for early-phase clinical trials and utilizes third-party contract development and manufacturing organizations for manufacturing services.
Summary from 10-K filed 2026-03-17
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenues | 1 | 2 | 709,000 | — | — | |
| Cost of revenues | 396,000 | 508,000 | 488,000 | 725,000 | 716,000 | |
| Gross profit | 803,000 | 2 | 221,000 | 497,000 | 590,000 | |
| General and administrative | 12 | 10 | 12 | 8 | 10 | |
| Research and development | 12 | 8 | 9 | 9 | 7 | |
| Total operating expenses | 24 | 18 | 21 | 19 | 18 | |
| Loss from operations | −23 | −17 | −21 | −18 | −17 | |
| Loss on disposal of assets | −97,000 | — | — | — | — | |
| Other income (expense), net | 680,000 | 549,000 | −377,000 | 300,000 | 411,000 | |
| Total other income (expenses), net | 583,000 | 549,000 | −384,000 | −792,000 | — | |
| Net loss | −23 | −16 | −21 | −19 | — | |
| Deemed dividend - warrant inducement offers | 0 | −9 | −798,000 | — | — | |
| Net loss attributable to common stockholders | −23 | −25 | −22 | −19 | — | |
| Basic net loss per share | −1.29 | −2.62 | −10.22 | −0.9 | −0.9 | |
| Diluted net loss per share | −1.29 | −2.62 | −10.22 | −0.9 | −0.9 | |
| Basic weighted average common shares outstanding | 17,577 | 9,411 | 2,173 | 21 | 19 | |
| Diluted weighted average common shares outstanding | 17,577 | 9,411 | 2,173 | 21 | 19 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 5 | 19 | 5 | 11 | 26 | |
| Prepaid expenses and other current assets | 686,000 | 308,000 | 376,000 | 404,000 | 282,000 | |
| Accounts and grants receivable | 104,000 | 84,000 | 111,000 | 218,000 | 55,000 | |
| Total current assets | 5 | 20 | 6 | 20 | 35 | |
| Property and equipment, net | 2 | 2 | 3 | 3 | 3 | |
| Intangible assets, net | 2 | 2 | 2 | 2 | 2 | |
| Operating lease asset | 513,000 | 882,000 | 1 | 2 | 2 | |
| Other assets | 176,000 | 202,000 | 193,000 | 244,000 | — | |
| Total assets | 10 | 26 | 12 | 27 | 43 | |
| Accounts payable | 423,000 | 99,000 | 638,000 | 2 | 645,000 | |
| Accrued expenses | 3 | 2 | 2 | 650,000 | 1 | |
| Current portion of operating lease liability | 655,000 | 623,000 | 593,000 | 564,000 | 537,000 | |
| Deferred revenue | 40,000 | 40,000 | 506,000 | — | — | |
| Total current liabilities | 4 | 3 | 4 | 5 | 3 | |
| Long-term portion of operating lease liability | 169,000 | 824,000 | 1 | 2 | — | |
| Other liabilities | 330,000 | 265,000 | 0 | — | — | |
| Total long-term liabilities | 499,000 | 1 | 1 | 2 | — | |
| Total liabilities | 5 | 4 | 5 | 7 | 5 | |
| Commitments and contingencies (Note 9) | — | — | — | — | — | |
| Preferred stock, $0.001 par value per share, 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and December 31, 2024 | — | — | — | — | — | |
| Additional paid-in capital | 138 | 131 | 92 | 84 | 81 | |
| Accumulated deficit | −132 | −110 | −85 | −63 | −44 | |
| Total stockholders equity | 6 | 22 | 7 | 21 | 37 | |
| Total liabilities and stockholders equity | 10 | 26 | 12 | 27 | 43 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 1 | 958,000 | 946,000 | 893,000 | — | |
| Interest earned on marketable securities | 0 | 60,000 | 220,000 | 170,000 | — | |
| Equity-based compensation | 2 | 2 | 2 | 2 | 1 | |
| Loss on disposal of assets | 97,000 | 0 | — | — | — | |
| Accounts and grants receivable | −20,000 | 27,000 | 107,000 | −164,000 | 366,000 | |
| Prepaid expenses and other current assets | −378,000 | 68,000 | 28,000 | −122,000 | −227,000 | |
| Other assets | 25,000 | −9,000 | 51,000 | −15,000 | −4,000 | |
| Accounts payable | 325,000 | −540,000 | −1 | 1 | −945,000 | |
| Deferred revenue | 0 | −466,000 | — | 307,000 | — | |
| Accrued expenses | 1 | −332,000 | 2 | −677,000 | −214,000 | |
| Operating lease asset and liability | −254,000 | −254,000 | −254,000 | — | — | |
| Other liabilities | 66,000 | 265,000 | — | — | — | |
| Net cash used in operating activities | −19 | −14 | −19 | −14 | −10 | |
| Proceeds from the sale of marketable securities | 0 | 352,000 | 9 | 179,000 | — | |
| Acquisition of property and equipment | −245,000 | −655,000 | −301,000 | −569,000 | −330,000 | |
| Acquisition of intangible assets | −350,000 | −337,000 | −393,000 | −287,000 | −980,000 | |
| Net cash used in investing activities | −595,000 | −640,000 | 8 | −677,000 | −11 | |
| Proceeds from the issuance of common stock, net of issuance cost | 5 | 13 | 5 | 2,000 | 27 | |
| Proceeds from warrants exercised, net of issuance cost | 0 | 16 | 98,000 | — | — | |
| Proceeds from stock subscription receivable | 0 | 100,000 | — | — | — | |
| Payments for taxes on RSUs vested and PSUs vested | −311,000 | −366,000 | −174,000 | — | — | |
| Net cash provided by financing activities | 5 | 29 | 5 | −509,000 | 45 | |
| Change in cash and cash equivalents | −15 | 14 | −6 | −15 | 25 | |
| Vesting of RSUs into Class A Common Stock | −797,000 | −1 | −777,000 | — | — | |
| Offering costs in accounts payable and accrued expenses | 28,000 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Longeveron Inc.'s CIK number?
Longeveron Inc.'s SEC CIK number is 0001721484 (1721484). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Longeveron Inc.'s SEC filings?
All of Longeveron Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Longeveron Inc. last report earnings?
Longeveron Inc. (LGVN) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-055806). This is Longeveron Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Longeveron Inc.'s most recent earnings 8-K?
Longeveron Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001213900-26-055806. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Longeveron Inc.'s latest earnings 8-K →
Look up any company's CIK number →